000650.SHE Renhe Pharmacy Co Ltd
- Market cap
- CNY 7.20B
- P/E
- 18.4x
- P/B
- 1.10x
- ROE
- 7.8%
- Dividend yield
- 2.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000650.SHE undervalued?
Graham number000650.SHE trades 5.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Renhe Pharmacy Co Ltd fundamental analysis
No fundamental analysis for Renhe Pharmacy Co Ltd yet.
Renhe Pharmacy Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Renhe Pharmacy Co Ltd
Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. The company offers Chinese and western medicines; and APIs and health-related products, including oral solid preparations, oral liquid preparations, large-volume injections, small-volume injections, external lotions, liniments, suppositories, ointments and other dosage forms of medicines, as well as health-related products. It also provides chemical raw materials and preparations; Chinese medicinal herbs; pro…
Full company profileRenhe Pharmacy Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Renhe Pharmacy Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.57B | 3.84B | 4.40B | 4.58B | 4.28B | 4.94B | 5.15B | 5.03B | 4.07B | 3.54B | 3.72B |
| Gross Profit | 1.30B | 1.49B | 1.88B | 1.93B | 1.67B | 1.86B | 1.85B | 1.84B | 1.53B | 1.31B | 1.36B |
| Operating Income | 550M | 570M | 753M | 826M | 882M | 1.04B | 953M | 899M | 775M | 717M | 726M |
| EBITDA | 612M | 618M | 838M | 873M | 874M | 1.01B | 991M | 1.08B | 787M | 781M | 804M |
| Net Income | 372M | 380M | 506M | 538M | 580M | 665M | 574M | 567M | 482M | 393M | 496M |
| EPS | 0.30 | 0.31 | 0.41 | 0.43 | 0.46 | 0.48 | 0.41 | 0.41 | 0.35 | 0.28 | 0.35 |
| Balance Sheet | |||||||||||
| Total Assets | 3.86B | 4.17B | 4.62B | 4.98B | 6.31B | 6.91B | 7.63B | 7.44B | 7.48B | 7.74B | 7.77B |
| Total Liabilities | 660M | 695M | 702M | 632M | 695M | 981M | 1.21B | 790M | 676M | 803M | 691M |
| Shareholders' Equity | 2.75B | 3.01B | 3.39B | 3.81B | 5.07B | 5.29B | 5.74B | 5.99B | 6.17B | 6.32B | 6.38B |
| Cash & Short-term Investments | 1.05B | 1.36B | 1.76B | 2.22B | 2.89B | 2.68B | 3.24B | 3.53B | 3.35B | 2.77B | 1.09B |
| Total Debt | - | - | - | - | 64.4M | 34.2M | 34.4M | 18.5M | 1.89M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 522M | 498M | 569M | 694M | 871M | 778M | 1.27B | 499M | 557M | 851M | - |
| Capital Expenditure | 59.9M | 43.6M | 70.1M | 144M | 218M | 500M | 221M | 187M | 286M | 74.6M | 39.2M |
| Free Cash Flow | 462M | 454M | 499M | 550M | 653M | 278M | 1.05B | 313M | 272M | 777M | 518M |
| Ratios | |||||||||||
| ROE | 13.5% | 12.6% | 14.9% | 14.1% | 11.4% | 12.6% | 10.0% | 9.5% | 7.8% | 6.2% | 7.8% |
| ROA | 9.6% | 9.1% | 11.0% | 10.8% | 9.2% | 9.6% | 7.5% | 7.6% | 6.4% | 5.1% | 6.4% |
| Net Profit Margin | 10.4% | 9.9% | 11.5% | 11.7% | 13.6% | 13.5% | 11.1% | 11.3% | 11.8% | 11.1% | 13.3% |
| Debt to Equity | - | - | - | - | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Renhe Pharmacy Co Ltd dividends
- Dividend yield
- 2.93%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 53.5%
- Ex-dividend date
- Jul 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 210M | 0.15 | 53.5% |
| 2024 | CNY 280M | 0.20 | 58.1% |
| 2023 | CNY 279M | 0.20 | 49.3% |
| 2022 | CNY 140M | 0.10 | 24.4% |
| 2021 | CNY 280M | 0.20 | 42.1% |
| 2020 | CNY 124M | 0.10 | 21.3% |
| 2019 | CNY 124M | 0.10 | 23.0% |
| 2018 | CNY 125M | 0.10 | 24.6% |
| 2017 | CNY 121M | 0.10 | 31.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 12.5:10 on May 26, 2015.
Who owns Renhe Pharmacy Co Ltd
- Insiders 32.46%
- Institutions 1.83%
- Public & others 65.71%
- Shares outstanding 1.40B
- Free float 963M
Renhe Pharmacy Co Ltd company profile
- Company name
- Renhe Pharmacy Co Ltd
- Ticker
- 000650.SHE
- ISIN
- CNE000000NF8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 18, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,923
- Fiscal year end
- December
- Address
- 998 Honggu Middle Avenue, Nanchang, China, 330038
- Phone
- 86 791 8389 6755
- Website
- renheyaoye.com
About Renhe Pharmacy Co Ltd
Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. The company offers Chinese and western medicines; and APIs and health-related products, including oral solid preparations, oral liquid preparations, large-volume injections, small-volume injections, external lotions, liniments, suppositories, ointments and other dosage forms of medicines, as well as health-related products. It also provides chemical raw materials and preparations; Chinese medicinal herbs; processed Chinese medicinal herbs; prepared Chinese medicines; antibiotics biological Sexually transmitted drugs; medical devices; sanitary materials; pharmaceutical machinery; and pharmaceutical packaging materials, as well as involved in the pharmaceutical commerce activities. The company was founded in 1996 and is based in Nanchang, China.
Renhe Pharmacy Co Ltd management
9- Mr. Wujun HuangGM & Director · born 1968
- Mr. Qiu Lin PengCFO & Non-Independent Director · born 1966
- Mr. Zi Qiang ZhangDeputy GM & Employee Director · born 1971
- Mr. Feng JiangSecretary of the Board & Non-Independent Director · born 1976
- Ms. Wanqiu LuoDeputy General Manager · born 1974
- Ms. Xin LiDeputy General Manager · born 1982
- Lingyun ZhuAccounting Supervisor
- Ms. Huijuan YangDeputy General Managers · born 1973
- Mr. Hailong TuDeputy General Manager · born 1970